Amneal is lined up to copy 2 of the blockbuster drugs on this tracker, which earned $6.5B combined in 2025.
| Drug | Brand owner | Copy | US LOE | Amneal's stage | 2025 brand sales |
|---|---|---|---|---|---|
| Prolia Boncresa |
Amgen | Biosimilar | 2025 | FDA-approved biosimilar | $4.4B |
| Xgeva Oziltus |
Amgen | Biosimilar | 2025 | FDA-approved biosimilar | $2.1B |
Each drug page lists sources for these entries. Brand sales show the size of the market, not Amneal's share of it.